Professor Rob Parton is a chief investigator for the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
Professor Rob Parton is a chief investigator for the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

3 January 2014

IMB researchers will help lead two of the Australian Research Council's (ARC) recently announced Centres of Excellence, which will commence funding this year.

ARC Centres of Excellence are prestigious foci of expertise through which high-quality researchers collaboratively maintain and develop Australia's international standing in research areas of national priority.

ARC Centre of Excellence in Advanced Molecular Imaging

Professor David Fairlie is one of 10 chief investigators from physics, chemistry, structural biology and immunology who will be working together to develop innovative imaging technologies and applying them to better understand the molecular basis of immunity and the interplay of immunological proteins.

The centre, led by Monash University, will receive $27.9 million in funding over 7 years. The centre will enable Australia to be an international leader in biological imaging, to train next generation interdisciplinary scientists, and to provide new insights for combating common diseases that afflict society.

Collaborating and partner organisations of the centre include:

  • The University of Melbourne
  • The University of Queensland
  • The University of New South Wales
  • La Trobe University
  • Synchrotron Light Source Australia Pty Ltd
  • University of Warwick, UK
  • Leica Microsystems Pty Ltd
  • Australian Nuclear Science and Technology Organisation
  • Carl Zeiss Pty Ltd
  • Deutsches Elektronen-Synchrotron, Germany

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology

Professor Rob Parton is one of 19 chief investigators from a multidisciplinary team who will be working together to understand and control the interface of materials with biological systems, with the ultimate goal of creating better diagnostic and therapeutic tools.

Nanomedicine is a rapidly emerging field revolutionising therapy in a wide range of diseases and the centre will focus on new scientific and social understanding, underpinning advances in bionanotechnology.

The centre, led by Monash University, will receive $26 million in funding over 7 years.

Collaborating and partner organisations of the centre include:

  • The University of Melbourne
  • The University of New South Wales
  • The University of Queensland
  • University of South Australia
  • Australian Nuclear Science and Technology Organisation
  • Commonwealth Scientific and Industrial Research Organisation
  • Imperial College London
  • Memorial Sloan-Kettering Cancer Center
  • Sung Kyun Kwan University
  • The University of Nottingham
  • University College Dublin
  • University of California, Santa Barbara
  • University of Warwick, UK
  • University of Wisconsin, Madison

ENDS

On this site

Go to top